Dr. Neelapu on Potential Advantages of Allogeneic CAR T-Cell Therapy in Lymphoma

Video

Sattva Neelapu, MD, discusses the potential advantages of allogeneic CAR T-cell therapy compared with autologous CAR T-cell therapy in lymphoma.

Sattva Neelapu, MD, professor of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the potential advantages of allogeneic CAR T-cell therapy compared with autologous CAR T-cell therapy in lymphoma.

Findings from the first-in-human phase 1 ALPHA study showed a manageable safety profile with the investigational anti-CD19 allogeneic CAR T-cell therapy ALLO-501 in combination with the anti-CD52 monoclonal antibody ALLO-647 in patients with relapsed/refractory large B-cell lymphoma or follicular lymphoma.

Longer follow-up is needed to assess whether allogeneic CAR T-cell therapy elicits similar efficacy and durability as autologous CAR T-cell therapy, says Neelapu. However, allogeneic CAR T-cell therapy may offer potential advantages over autologous CAR T-cell therapy.

These potential advantages include reduced manufacturing cost, increased accessibility for patients, and lower treatment cost for patients, concludes Neelapu.

Recent Videos
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at David Geffen School of Medicine at University of California, Los Angeles (UCLA)
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.